Telix Pharma keeps guidance after strong Q1 result

The news: Telix Pharmaceuticals has reaffirmed its full-year revenue guidance after posting strong first-quarter growth generated from its prostate cancer imaging product Illuccix.

The numbers: Telix said total revenue for the three months to 31 March rose to USD186 million ($292 million), an increase of 62% from a year ago. It reiterated full-year revenue is expected to be in the range of USD770 million to USD800 million.

The context: CEO Christian Behrenbruch said Illuccix has continued its momentum, gaining market share and maintaining price stability in a competitive landscape. The Melbourne-headquartered Telix is the only company with two US FDA-approved PET imaging agents, Illuccix and Gozellix, which is to be launched in the US in the June quarter.

Telix reaffirmed that it does not expect any material impact on its business or supply chain as a result of the international trade tariffs announced by the US government on 2 April or the subsequent inclusion of pharmaceuticals.